These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35392566)

  • 1. Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design.
    Lai LY; Arshad F; Areia C; Alshammari TM; Alghoul H; Casajust P; Li X; Dawoud D; Nyberg F; Pratt N; Hripcsak G; Suchard MA; Prieto-Alhambra D; Ryan P; Schuemie MJ
    Front Pharmacol; 2022; 13():837632. PubMed ID: 35392566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of epidemiologic methods for active surveillance of vaccine safety.
    McClure DL; Glanz JM; Xu S; Hambidge SJ; Mullooly JP; Baggs J
    Vaccine; 2008 Jun; 26(26):3341-5. PubMed ID: 18462849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program.
    Baker MA; Lieu TA; Li L; Hua W; Qiang Y; Kawai AT; Fireman BH; Martin DB; Nguyen MD
    Am J Epidemiol; 2015 Apr; 181(8):608-18. PubMed ID: 25769306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine Safety Surveillance Using Routinely Collected Healthcare Data-An Empirical Evaluation of Epidemiological Designs.
    Schuemie MJ; Arshad F; Pratt N; Nyberg F; Alshammari TM; Hripcsak G; Ryan P; Prieto-Alhambra D; Lai LYH; Li X; Fortin S; Minty E; Suchard MA
    Front Pharmacol; 2022; 13():893484. PubMed ID: 35873596
    [No Abstract]   [Full Text] [Related]  

  • 7. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When should case-only designs be used for safety monitoring of medical products?
    Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data.
    Cai Y; Du J; Huang J; Ellenberg SS; Hennessy S; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2017 Jul; 17(Suppl 2):76. PubMed ID: 28699543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.
    Anglemyer A; Horvath HT; Bero L
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):MR000034. PubMed ID: 24782322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
    Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods.
    Leite A; Andrews NJ; Thomas SL
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):225-37. PubMed ID: 26817940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing self-controlled case series data when case confirmation rates are estimated from an internal validation sample.
    Xu S; Clarke CL; Newcomer SR; Daley MF; Glanz JM
    Biom J; 2018 Jul; 60(4):748-760. PubMed ID: 29768667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On Measuring Vaccine Effectiveness with Observational Study Designs.
    Habibzadeh F; Habibzadeh P; Yadollahie M
    Acta Med Acad; 2022 Aug; 51(2):134-146. PubMed ID: 36318007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future.
    Alomar M; Tawfiq AM; Hassan N; Palaian S
    Ther Adv Drug Saf; 2020; 11():2042098620938595. PubMed ID: 32843958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety.
    Li R; Stewart B; Weintraub E
    J Biopharm Stat; 2016; 26(4):686-93. PubMed ID: 26098696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
    Varricchio F; Iskander J; Destefano F; Ball R; Pless R; Braun MM; Chen RT
    Pediatr Infect Dis J; 2004 Apr; 23(4):287-94. PubMed ID: 15071280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.